When asking doctors whether or not they have been prescribing a drug, specialty sales rep David Schwartz's advice is, "Don't accept yes or no for an answer."
When asking doctors whether or not they have been prescribing a drug, specialty sales rep David Schwartz's advice is, "Don't accept yes or no for an answer." Though many reps take a doctor's hurried, positive answer as a sign that their work is done, Schwartz's work has just begun. "It's time to start asking questions," he said. To Schwartz, a rep's job is just as much about listening to doctors as it is about detailing products.
The Pharmacia & Upjohn rep, a seven-time winner of the company's Premiere Award Now (formerly called the Upjohn Academy), practiced pharmacy for one and a half years before turning to sales. "I always thought it would be fun to meet the doctors that called in the prescriptions," he said. "It was the best move I ever made."
This expertise has given Schwartz what he admits is "a huge edge," in sales. Still a registered pharmacist, Schwartz completes 12 hours of continuing education per year and is an active member of the Harris Co. Pharmacy Association. "I always try to teach [new reps] the importance of calling on pharmacists," he said.
Schwartz remembers many Saturdays early in his 26-year career detailing pharmacists on his days off from physicians' calls.
His satisfaction comes from making a difference. "When a doctor sees you in the hall and says, 'You saved my patient's life last night,' that's a real nice feeling," he said. But his favorite part of being a rep? "Talking, and meeting people," he said with a laugh. "I love my job."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.